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Summary
Bile acids (BAs) play important roles not only in lipid metabolism, but
also in signal transduction. TGR5, a transmembrane receptor of BAs, is
an immunomodulative factor, but its detailed mechanism remains
unclear. Here, we aimed to delineate how BAs operate in immunological
responses via the TGR5 pathway in human mononuclear cell lineages.
We examined TGR5 expression in human peripheral blood monocytes,
several types of in vitro differentiated macrophages (M/s) and dendritic
cells. M/s differentiated with macrophage colony-stimulating factor and
interferon-c (Mc-M/s), which are similar to the human intestinal lamina
propria CD14+ M/s that contribute to Crohn’s disease (CD) pathogene-
sis by production of pro-inflammatory cytokines, highly expressed TGR5
compared with any other type of differentiated M/ and dendritic cells.
We also showed that a TGR5 agonist and two types of BAs, deoxycholic
acid and lithocholic acid, could inhibit tumour necrosis factor-a produc-
tion in Mc-M/s stimulated by commensal bacterial antigen or lipopoly-
saccharide. This inhibitory effect was mediated by the TGR5–cAMP
pathway to induce phosphorylation of c-Fos that regulated nuclear fac-
tor-jB p65 activation. Next, we analysed TGR5 levels in lamina propria
mononuclear cells (LPMCs) obtained from the intestinal mucosa of
patients with CD. Compared with non-inflammatory bowel disease,
inflamed CD LPMCs contained more TGR5 transcripts. Among LPMCs,
isolated CD14+ intestinal M/s from patients with CD expressed TGR5.
In isolated intestinal CD14+ M/s, a TGR5 agonist could inhibit tumour
necrosis factor-a production. These results indicate that TGR5 signalling
may have the potential to modulate immune responses in inflammatory
bowel disease.
Keywords: bile acid; Crohn’s disease; intestinal macrophage; TGR5;
tumour necrosis factor a.
Abbreviations: BA, bile acid; CA, cholic acid; CD, Crohn’s disease; CDCA, chenodeoxycholic acid; CHO, Chinese hamster ovary;
DC, dendritic cell; DCA, deoxycholic acid; GM-CSF, granulocyte–macrophage colony-stimulating factor; GM-M/, macrophage
derived by GM-CSF; HBSS, Hanks’ Balanced Salt solution; IBD, inflammatory bowel disease; IFN, interferon; IjBa, inhibitor of
nuclear factor-jBa; IL, interleukin; LCA, lithocholic acid; LP, lamina propria; LPMC, lamina propria mononuclear cell; LPS,
lipopolysaccharide; MACS, magnetic cell separation system; M-CSF, macrophage colony-stimulating factor; M/, macrophage;
M-M/, macrophage derived by M-CSF; Mc-M/, derived by M-CSF and IFN-c; MOI, multiplicity of infection; p-c-Fos,
phospho-c-Fos; p-IjBa, phospho-IjBa; RT-qPCR, real time-quantitative polymerase chain reaction; TNF, tumour necrosis
factor; UDCA, ursodeoxycholic acid
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Introduction
The immune system is intricately constituted to maintain
homeostasis and avoid excessive or deficient responses
against foreign antigens, which causes immunological dis-
orders. Recently, macrophages (M/s), major components
of innate immunity, were circumstantially analysed for
their characteristics. The study showed that M/s have
several subpopulations1,2 that were classified broadly into
two categories: an inflammatory phenotype that is stimu-
lated to produce pro-inflammatory cytokines such as
tumour necrosis factor-a (TNF-a) or an anti-inflamma-
tory phenotype that induces immune tolerance by pro-
ducing interleukin-10 (IL-10).
Macrophages have been also classified according to their
anatomical locations. Intestinal M/s play a role in the
maintenance of immunological homeostasis by regulation
of some inflammatory cytokines against foreign antigens
such as commensal bacteria, even if phagocytic and bacteri-
cidal activity remains.2,3 We previously reported that mouse
intestinal M/s produce IL-10 in response to bacterial
stimulation, which prevents an excess immune response.4
Furthermore, we identified that there are two subsets of
resident mouse intestinal M/s, and monocyte chemoattrac-
tant protein-1 is important for the composition of IL-10-
producing intestinal M/s.5 Denning et al.6 also reported
that intestinal M/s can induce regulatory T cells.
Inflammatory bowel disease (IBD), including Crohn’s
disease (CD) and ulcerative colitis, is caused by inade-
quate immunological responses against luminal antigens,
which results in chronic inflammation in some intestinal
regions.7 In IBD, the homeostatic function of intestinal
M/s is disrupted and abnormal immune responses of
intestinal M/s contribute to the development of chronic
inflammation. In fact, it has been reported that M/s
expressing the innate-immune receptor CD14 infiltrate
the intestinal mucosa of patients with IBD.8–10 TREM-1+
M/s in the lamina propria (LP) of patients with IBD
mediate chronic inflammation.11 We also demonstrated
that intestinal CD68+ M/s in patients with CD produce
most of the IL-18 that contributes to the promotion of
the T helper type 1 immune response.12 Recently, we have
identified unique CD33+ CD14+ CD68+ intestinal M/s
that strongly contribute to CD pathogenesis by their pro-
inflammatory cytokine production and antigen presenta-
tion function that cooperates with T cells and mucosal
natural killer cells.10,13,14 Therefore, conditioning of
innate immune cells to an immunoregulatory phenotype
may become a novel therapeutic strategy. We previously
reported that bile acids (BAs) and synthetic retinoic acid
receptor agonists can induce IL-12-hypoproducing den-
dritic cells (DCs).15,16
Bile acids play important roles not only in lipid metabo-
lism, but also in signal transduction via several receptors.
TGR5, a G-protein coupled receptor, was identified by an
exhaustive search of the GenBank DNA database.17,18
TGR5 gene expression covers a broad area to varying
degrees,17–19 including the hepatobiliary system such as
liver sinusoidal endothelial cells,20 gallbladder epithelial
cells21 and elsewhere. TGR5 is considered to be closely
associated with various biological functions. In metabolism,
BAs promote energy expenditure in brown adipose tissue
via activated thyroid hormone,22 and they increase intesti-
nal glucagon-like peptide-1 secretion for glucose homeo-
static control.23 In the immune system, BAs are classically
known to inhibit inflammatory cytokine production.24,25
In terms of the immunological function of TGR5, it has
recently become evident that CD14+ monocytes show high
TGR5 expression16,17 and TGR5 expresses on some M/s,
such as Kupffer cells.26 A TGR5 agonist inhibits an athero-
sclerosis reduced by M/ inflammation.27 These results
suggest that TGR5 can regulate innate immunity.
There are only a few reports detailing the relationships
between TGR5 and gut immunity. In an experimental
mouse colitis model, TGR5 regulates intestinal inflamma-
tion by a reduction in inflammatory cytokines.28 However,
there is no report of a survey of human intestinal samples
in terms of gut immunological regulation by TGR5.
Recently, we have found that M/s differentiated by mac-
rophage colony-stimulating factor (M-CSF) and inter-
feron-c (IFN-c) (Mc-M/s) show a similar phenotype to
that of intestinal CD14+ M/s, which evoke inflammation
in patients with IBD, in terms of cytokine production
including TNF-a, IL-6 and IL-23, and the expression pat-
tern of cell surface markers.10 We hypothesized that Mc-
M/s mimic LP CD14+ M/s expressing TGR5, and TGR5
signalling can suppress the production of pro-inflamma-
tory cytokines by inflammatory M/s. In the present
study, we investigated TGR5 expression in several innate
immune cell populations, including Mc-M/s differentiated
in vitro and the intestinal CD14+ M/s of patients with
CD, and whether a TGR5 agonist can suppress pro-
inflammatory cytokine production by these cells.
Materials and methods
Heat-treated bacterial antigen
Gram-positive Enterococcus faecalis (ATCC29212) was
cultured in brain–heart infusion medium. Bacteria were
harvested and washed twice with ice-cold PBS (Wako
Chemicals, Osaka, Japan). Bacterial suspensions were
heated at 80° for 30 min, washed, resuspended in PBS
and stored at  80°. Complete killing was confirmed by
24 hr incubation at 37° on solid growth medium.
In vitro monocyte differentiation
Peripheral blood mononuclear cells were isolated from
heparinized peripheral blood samples by density gradient
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centrifugation using Lymphoprep (Nycomed Pharma,
Oslo, Norway). Cells were aspirated from the gradient
interface, washed in PBS, and resuspended at 1 9 106
cells/ml in RPMI-1640 medium (Sigma-Aldrich, St Louis,
MO) containing 10% heat-inactivated fetal bovine serum
(BioSource, Camarillo, CA), 100 U/ml penicillin and
100 mg/ml streptomycin (Invitrogen, La Jolla, CA).
Monocytes were purified using a magnetic cell separation
system (MACS; Miltenyi Biotec, Auburn, AL) with anti-
human CD14 microbeads (Miltenyi Biotec). Monocytes
were seeded in dishes at a density of 1 9 106 cells/2 ml
culture medium. Based on a review of monocyte differen-
tiation,29 some cultures contained 50 ng/ml M-CSF
(R&D Systems, Minneapolis, MN) for M-CSF-differenti-
ated macrophages (M-M/s), 50 ng/ml M-CSF and
100 ng/ml IFN-c (R&D) for Mc-M/s, 50 ng/ml granulo-
cyte–macrophage colony-stimulating factor (GM-CSF)
(R&D) for GM-CSF-differentiated macrophages (GM-M/
s) or 20 ng/ml GM-CSF and 20 ng/ml IL-4 (R&D) for
DCs. After 1, 3 and 6 days, cells were collected. We
defined stimulated monocytes for 6 days as completely
differentiated. Some samples were used for real-time
quantitative PCR (RT-qPCR), immunofluorescence and
Western blot analyses.
Peripheral blood samples were collected from healthy
donors after obtaining written informed consent. All
experiments were approved by the Institutional Review
Board of the Keio University School of Medicine.
RT-qPCR analyses
Total RNA was isolated from monocytes using an RNeasy
Micro Kit (Qiagen, Washington DC) and reverse tran-
scribed using a Primescript RT Reagent Kit (Takara Bio
Inc., Otsu, Japan) according to the manufacturer’s
instructions. RT-qPCR was performed using a TaqMan
Universal PCR Master Mix (Applied Biosystems, Foster
City, CA) with gene-specific primers for TGR5
(Hs01937849_s1) and b-actin (Hs99999903_m1) as an
internal control. The PCR amplifications were performed
using a DNA Engine Opticon 2 system or CFX96 Real-
Time System (Bio-Rad, Hercules, CA), and data were
analysed with OPTICON MONITOR software (MJ Research,
Waltham, MA).
TGR5 immunofluorescence
Cells were fixed with 4% paraformaldehyde and blocked
in Protein Block serum-free Ready-To-Use (Dako,
Glostup, Denmark) for 1 hr at room temperature. Then,
cells were incubated with a rabbit anti-TGR5 antibody
(Abcam, Cambridge, MA) for 2 hr, followed by an Alexa
Fluor 568-conjugated goat anti-rabbit IgG (Molecular
Probes, Eugene, OR) for 1 hr, while protected from light.
Nuclei were counterstained with Hoechst 33342
trihydrochloride, trihydrate (Invitrogen). The fluorescence
images obtained were analysed by LUMINA VISION software
(Mitani, Tokyo, Japan).
Stimuli for differentiated monocytes
Differentiated monocytes described above were seeded in
96-well culture dishes at a density of 2 9 105 cells/200 ll
culture medium. Then, cells were stimulated with the
following: heat-killed E. faecalis (multiplicity of infec-
tion = 100), lipopolysaccharide (LPS; Sigma), BAs;
chenodeoxycholic acid (CDCA; Sigma), deoxycholic acid
(DCA; Sigma), lithocholic acid (LCA; Sigma), cholic acid
(CA; Nacalai Tesque, Kyoto, Japan) or ursodeoxycholic
acid (UDCA; Tokyo Chemical Industry, Tokyo, Japan), a
3-(2-chlorophenyl)-N-(4-chlorophenyl)-N,5-dimethylisox-
azole-4-carboxamide as a TGR5 agonist (Bio Vision,
Mountain View, CA) which was derived by Evans et al.30
(Fig. 1), a p38 mitogen-activated protein kinase inhibitor
(Merck Millipore, Tokyo, Japan), a toll-like receptor 4
inhibitor (Imgenex, San Diego, CA) or 8-bromoadenosine
3′, 5′-cyclic monophosphate as a cAMP reagent (Sigma).
After 1 day of stimulation, supernatants were collected
for cytokine assays, and the remaining cells were used for
viability assays.
Flow cytometry
For labelling cell surface markers, monoclonal antibodies
against CD14, CD33, CD205, CD206, CD209, CD80,
CD86, CD1a, CD40, PD-L1, PD-L2, CD16, CD32 and
CD64 were purchased from BD Pharmingen (San Jose,
CA). Monoclonal antibody against TGR5 was purchased
from R&D. The fluorescence intensity of labelled cell sur-
face markers was assessed using an FACS Calibur flow
cytometer (BD), and the data were analysed using CELL-
QUEST (BD) or FLOWJO (TreeStar Inc., Ashland, OR) soft-
ware. Dead cells were excluded from analyses by
propidium iodide staining.
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Figure 1. Chemical structure of the 3-(2-chlorophenyl)-N-(4-chlor-
ophenyl)-N, 5-dimethylisoxazole-4-carboxamide as the TGR5 agonist
we used in this study. This compound precursor was discovered by a
high-throughput screening of the GlaxoSmithKline Pharmaceuticals
(Collegeville, PA) compound library using a luciferase assay, the pro-
duction of which was caused by cAMP. In the process of exploring
substitution derivative analysis, this TGR5 agonist was found out as
a high affinity for TGR5 (pEC50 = 68) of U2-OS cells.
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Analysis of cytokine production
Production levels of TNF-a were assessed using a Human
Inflammation Cytometric Bead Array Kit (BD) with the
FACS Calibur, according to the manufacturer’s
instructions.
cAMP production assay
Mc-M/s (1 9 105 cells) were treated with the TGR5
agonist (10 lM) for 5 min in the presence of 1 mM 3-
isobutyl-1-methylxanthine (Sigma). The amount of cAMP
was determined with a cAMP-Screen System (Applied
Biosystems).
Western blotting
Mc-M/s stimulated by 10 ng/ml LPS and 10 lM TGR5
agonist were used for intracellular signalling protein
detection. Cells (1 9 105 cells/well of a 96-well plate)
were washed with ice-cold PBS containing 01% protease
inhibitor cocktail (Sigma), and then lysed in 15 ll RIPA
buffer (Thermo Fisher Scientific, Waltham, MA) contain-
ing 05% protease inhibitor cocktail (Sigma) and 1 mM
Na3VO4. After centrifugation, supernatants mixed with
lithium dodecyl sulphate sample buffer and reducing
agents (Invitrogen) were electrophoresed on a Mini PRO-
TEAN TGX gel (Bio-Rad). Separated proteins were trans-
ferred by an iBlot Dry Blotting System (Invitrogen)
according to the manufacturer’s instructions. The mem-
brane was immersed in Starting Block T20 (TBS) Block-
ing Buffer (Thermo Fisher Scientific) for 1 hr. After
blocking, primary antibodies were added to the mem-
branes, followed by incubation at 4° overnight. After
incubation with a horseradish peroxidase-conjugated anti-
rabbit secondary antibody (Cell Signaling, Danvers, MA),
blots were visualized using an Amersham ECL Prime wes-
tern Blotting Detection Reagent (GE Healthcare, Bucking-
hamshire, UK) and analysed using an ImageQuant LAS
4000 mini (GE Healthcare). The antibodies used were
anti-phospho-c-Fos, anti-c-Fos and anti-b-actin (all Cell
Signaling). Immunoblotted membranes were repeatedly
used after treatment with a Ten-min Western Blot Re-
Probe Kit (Jacksun Easy Biotech, Bronx, NY).
Tissue samples
Normal intestinal mucosa was obtained from macroscopi-
cally and microscopically unaffected areas in patients with
colon cancer as non-IBD samples. Intestinal IBD mucosa
was obtained from surgically resected specimens taken
from patients with CD and diagnosed based on clinical,
radiographic, endoscopic and histological findings,
according to established criteria. All experiments were
approved by the Institutional Review Board of Keio
University School of Medicine and Yokohama Municipal
Citizen’s Hospital, Inagi Municipal Hospital, and written
informed consent was obtained from all patients.
Analysis of lamina propria mononuclear cells
Lamina propria mononuclear cells (LPMCs) were isolated
from intestinal specimens using a technique described
elsewhere,31 with some modification. Briefly, dissected
mucosa was incubated in calcium and magnesium-free
Hanks’ balanced salt solution (HBSS) (Sigma) containing
25% heat-inactivated fetal bovine serum and 1 mM dith-
iothreitol (Sigma) to remove mucus. The mucosa was
then incubated twice in HBSS containing 1 mM EDTA
(Sigma) for 45 min at 37°. Tissues were collected and
incubated in HBSS containing 1 mg/ml collagenase type 3
and 01 mg/ml DNase I (Worthington Biochemical, Lake-
wood, CO) for 60 min at 37°. Cells were pelleted and
resuspended in a 40% Percoll solution (GE Healthcare),
and then layered onto 60% Percoll before centrifugation
for 20 min at room temperature. Viable LPMCs were
recovered from the 40–60% layer interface. CD14+,
CD3+, CD56+ and CD14 CD3 CD56 subsets of
LPMCs were purified using MACS. Cells were used for
RT-qPCR analysis of TGR5 and the cytokine production
assay.
Cell viability assay
PrestoBlue Cell Viability Reagent (Invitrogen), diluted at
1 : 10 with medium, was added to differentiated mono-
cytes (2 9 105 cells/100 ll diluted solution) in a 96-well
plate. Samples were then incubated for 30 min at 37°.
PrestoBlue is reduced from blue resazurin to red redoru-
fin in the presence of viable cells. Fluorescence (excita-
tion, 570 nm; emission, 600 nm) was measured with a
Benchmark plus (Bio-Rad).
Statistical analysis
Statistical analyses were performed using GRAPHPAD PRISM
software version 4.0 (GraphPad Software Inc., San Diego,
CA). Kruskal–Wallis one-way analysis of variance and the
Bonferroni post-hoc test were used for examining statisti-
cal differences among more than three groups, and the
Student’s t-test was used for two groups. A value of
P < 005 was considered statistically significant.
Results
Expression of TGR5 in Mc-M/s compared with other
peripheral blood monocytes
To investigate the expression of TGR5 among several
phenotypes of innate immune cells, we first used
© 2013 Blackwell Publishing Ltd, Immunology, 139, 19–2922
K. Yoneno et al.
RT-qPCR to analyse the TGR5 mRNA level in several
types of mononuclear cell lineages differentiated from
peripheral blood. The results showed that TGR5 mRNA
was down-regulated in almost all M/s and DCs differen-
tiated in vitro, except for Mc-M/s. On day 1, Mc-M/s
maintained their TGR5 mRNA level at the same level as
that of peripheral CD14+ monocytes (Fig. 2a). We con-
firmed that maintenance of the TGR5 mRNA level
occurred in an IFN-c concentration-dependent manner
(Fig. 2b). The TGR5 mRNA level of Mc-M/s was con-
served on day 6 (Fig. 2c). In addition, when IFN-c was
added to differentiated M-M/s on day 6, IFN-c did not
affect the TGR5 mRNA level (Fig. 2d). These findings
suggest that IFN-c stimulation at the initial phase of dif-
ferentiation is important to maintain the TGR5 mRNA
level in M/s. We also analysed TGR5 expression by
immunofluorescence and flow cytometry. Mc-M/s
expressed more TGR5 proteins than M-M/s (Fig. 2e,f).
The morphology and expression of cell surface markers in
Mc-M/s and M-M/s were shown in the Supplementary
material, Fig. S1.
A TGR5 agonist suppresses bacterially induced
reduction of TNF-a in Mc-M/s
To demonstrate the anti-inflammatory function of TGR5
signalling in Mc-M/s, we analysed the inhibitory effect of
a TGR5 agonist on TNF-a production in Mc-M/s stimu-
lated with commensal bacterial antigen. As expected, the
TGR5 agonist significantly suppressed TNF-a production
in a concentration-dependent manner (Fig. 3a). This
function was not affected by DMSO (see Supplementary
material, Fig. S2). The TGR5 agonist did not act in other
types of M/s and DCs, which did not express TGR5 (see
Supplementary material, Fig. S3a–c). To confirm that this
suppressive function caused an effect on TNF-a produced
via the toll-like receptor 4 pathway correctly, we used
LPS instead of E. faecalis for stimulation of Mc-M/s. We
also found that the TGR5 agonist suppressed LPS-
induced TNF-a production (Fig. 3b), but it did not affect
anti-inflammatory cytokine, IL-10 production (see Sup-
plementary material, Fig. S4). This TGR5 agonist did not
change the cell surface marker on the Mc-M/s (see Sup-
plementary material, Fig. S5). With regard to peripheral
CD14+ monocytes, which express TGR5, the TGR5 ago-
nist suppressed TNF-a production as well (see Supple-
mentary material, Fig. S6). Furthermore, we analysed
whether BAs could suppress TNF-a production in the
same manner as that of the TGR5 agonist. As shown in
Fig. 3(c), DCA and LCA, which are considered natural
TGR5 ligands, suppressed TNF-a production. The viabil-
ity of Mc-M/s treated with the TGR5 agonist and BAs
was not significantly altered (Fig. 3d,e). To compare with
a TGR5 agonist, we used a toll-like receptor 4 inhibitor
and a p38 mitogen-activated protein kinase inhibitor for
the evaluation of TNF-a inhibition. The inhibitory effect
of TGR5 agonist was comparable with that of p38 mito-
gen-activated protein kinase inhibitor on TNF-a produc-
tion at 10 mM concentration (Fig. 3f). It suggests that a
TGR5 agonist has an anti-inflammatory effect that com-
pares favourably with other types of anti-inflammatory
reagents.
cAMP, a second messenger of TGR5, also suppresses
TNF-a production in Mc-M/s
We next investigated whether cAMP, a downstream
molecule of TGR5, could suppress TNF-a production in
Mc-M/s. As shown in Fig. 4(a, b), cAMP also suppressed
TNF-a production in a similar way to the suppression by
the TGR5 agonist in Mc-M/s stimulated with E. faecalis
or LPS. The viability of Mc-M/s modified by cAMP was
not significantly altered (Fig. 4c). Consistent with previ-
ous reports,16–18,23,27,28 the TGR5 agonist also up-regu-
lated cAMP in Mc-M/s (Fig. 4d) and induced
phosphorylation of c-Fos (Fig. 4e) after LPS stimulation.
Intestinal CD14+ M/s from CD patients express
TGR5
We previously reported that intestinal CD14+ M/s con-
tribute to the pathogenesis of CD by the production of
a large amount of pro-inflammatory cytokines in
response to bacterial stimulation.10 We investigated
whether TGR5 expression in the intestinal CD14+ M/s
of CD patients was the same as that in in vitro Mc-M/s
that mimic CD14+ M/s. The TGR5 mRNA level in
LPMCs obtained from inflamed CD mucosa, which was
distinguished by TNF-a production (see Supplementary
material, Fig. S7), exhibited significantly up-regulated
TGR5 mRNA, compared with that in the LPMCs of
patients without IBD (Fig. 5a). Moreover, isolated
CD14+ M/s highly expressed TGR5 mRNA, compared
with CD14+ M/-depleted LPMCs (Fig. 5b). These find-
ings revealed that intestinal CD14+ M/s are the cells
that express TGR5 among LPMCs. Importantly, the
TGR5 agonist suppressed bacterially stimulated TNF-a
production in CD LPMCs (Fig. 6a) and isolated CD14+
M/s (Fig. 6b).
Discussion
In this study, we demonstrated that TGR5, which is a G-
protein coupled receptor for BAs, is expressed in both the
Mc-M/s and intestinal CD14+ M/s of patients with CD,
which produce large amounts of TNF-a in response to
bacterial stimuli, and that a TGR5 agonist can suppress
such a response. It has been reported that TGR5 is
expressed in human peripheral monocytes.16,17 Although
transcriptional regulation of TGR5 has not been identi-
© 2013 Blackwell Publishing Ltd, Immunology, 139, 19–29 23
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Figure 2. Macrophages differentiated with macrophage colony-stimulating factor and interferon-c (Mc-M/s) differentiated from peripheral blood
CD14+ monocytes maintain TGR5 expression. (a) The mRNA level of TGR5 in the CD14 fraction of peripheral blood mononuclear cells
(PBMCs), CD14+ monocytes and M/s differentiated with macrophage colony-stimulating factor alone (M-M/s), dendritic cells (DCs), M/s dif-
ferentiated with granulocyte–macrophage colony-stimulating factor and interferon-c (GM-M/s) and Mc-M/s on day 1 was measured by real-
time quantitative PCR. The mRNA level of TGR5 was normalized to that of b-actin, and is shown as the fold change based on the mRNA levels
in the CD14 fraction. Results are shown as the means  SEM from three independent experiments. Statistical analysis was performed by Krus-
kal–Wallis one-way analysis of variance (ANOVA)and the Bonferroni post-hoc test for multiple comparisons. *P < 005, Mo: monocytes, GM: GM-
M/s, DC: dendritic cells, M: M-M/s, Mc: Mc-M/s. (b) The mRNA level of TGR5 in differentiated Mc-M/s for each interferon-c concentration
(0, 1, 33 and 100 ng/ml) on day 1. The mRNA level of TGR5 was normalized to that of b-actin, and is shown as the fold change based on the
mRNA levels in M/s without interferon-c stimulation. Results are shown as the means  SEM from five independent experiments. Statistical
analysis was performed by Kruskal–Wallis one-way ANOVA and the Bonferroni post-hoc test for multiple comparisons. *P < 005, **P < 001. (c)
The mRNA level of TGR5 in differentiated M-M/s and Mc-M/s on day 1, 3 and 6. The mRNA level of TGR5 was normalized to that of b-actin,
and is shown as the fold change based on the mRNA level in M-M/s on day 1. Results are shown as the means  SEM from five independent
experiments. Statistical analysis was performed by Kruskal–Wallis one-way ANOVA and the Bonferroni post-hoc test for multiple comparisons.
*P < 005, **P < 001. (d) The mRNA level of TGR5 in the CD14 fraction of PBMCs, CD14+ monocytes (Mo) and differentiated M-M/s on
day 7, which were stimulated with or without interferon-c on day 6. The mRNA level of TGR5 was normalized to that of b-actin, and is shown
as the fold change based on the mRNA levels in CD14 fraction of PBMCs. Results are shown as the means  SEM from four independent
experiments. Statistical analysis was performed by Kruskal–Wallis one-way ANOVA and the Bonferroni post-hoc test for multiple comparisons. (e)
Fluorescence imaging of M-M/s and Mc-M/s on day 6 of differentiation are shown. Mc-M/s stained with the secondary antibody only was
shown as the negative control. Red: TGR5, Blue: nuclei. (f) Flow cytometry analysis for TGR5 expression of differentiated M-M/s and Mc-M/s
(on day 6). The shaded histogram shows the profiles of the TGR5 antibody staining and the open histogram shows staining with the isotype
control.
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Figure 3. A TGR5 agonist and bile acids (BAs) suppress tumour necrosis factor-a (TNF-a) production from macrophages differentiated with
macrophage colony-stimulating factor (M-CSF) and interferon-c (IFNc) (Mc-M/s) stimulated by Enterococcus faecalis or lipopolysaccharide
(LPS). (a) The Mc-M/s were differentiated from CD14+ monocytes with M-CSF and IFNc; 50 and 100 ng/ml, respectively). After 6 days in cul-
ture, TNF-a levels in culture supernatants were analysed after 24 hr of stimulation with E. faecalis (multiplicity of infection = 100) with or with-
out the TGR5 agonist (1, 33 and 10 lM). Results are shown as the means  SEM from seven independent experiments as relative percentages of
the TNF-a levels in Mc-M/s stimulated with E. faecalis only. Statistical analysis was performed by Kruskal–Wallis one-way analysis of variance
(ANOVA) and the Bonferroni post-hoc test for multiple comparisons. **P < 001. (b) Similar TNF-a analysis to that in (a), stimulated with LPS
(100 ng/ml) with or without the TGR5 agonist. Results are shown as the means  SEM from five independent experiments as relative percent-
ages of the TNF-a levels in Mc-M/s stimulated with LPS only. Statistical analysis was performed by Kruskal–Wallis one-way ANOVA and the Bon-
ferroni post-hoc test for multiple comparisons. **P < 001. (c) Several BAs inhibited TNF-a production, which was promoted by E. faecalis
(multiplicity of infection = 100) after 24 hr of stimulation, from Mc-M/s on day 6. Results are shown as the means  SEM from three indepen-
dent experiments as relative percentages of the TNF-a levels in Mc-M/s stimulated with E. faecalis only. Statistical analysis was performed by
Kruskal–Wallis one-way ANOVA and the Bonferroni post-hoc test for multiple comparisons. *P < 005, **P < 001. CA, cholic acid; DCA, deoxy-
cholic acid; CDCA, chenodeoxycholic acid; LCA, lithocholic acid; UDCA, ursodeoxycholic acid; (d, e) Cell viability of peripheral blood mononu-
clear cell-derived Mc-M/s. Mc-M/s were differentiated from monocytes by 6 days of culture with M-CSF and IFNc (control). Other stimuli
were added on day 6; TGR5 agonist (1, 33 and 10 lM) in (d), and BAs including CA, DCA, CDCA, LCA and UDCA in (e). Cell viability was
measured by PrestoBlue Cell Viability Reagent. Results are shown as the means  SEM from each three independent experiments as relative
percentages of the viability of Mc-M/s stimulated with E. faecalis only. Statistical analysis was performed by Kruskal–Wallis one-way ANOVA.
(f) TNFa levels in Mc-M/s culture supernatants were analysed after 24 hr stimulation with LPS (100 ng/ml) with or without the inflammatory
agents as follows: TGR5 agonist, toll-like receptor (TLR) 4 inhibitor and p38 mitogen-activated protein kinase (MAPK) inhibitor. Results are
shown as the means  SEM from three independent experiments as relative percentages of TNFa levels in Mc-M/s stimulated with LPS only.
Statistical analysis was performed by Kruskal–Wallis one-way ANOVA and the Bonferroni post-hoc test for multiple comparisons. **P < 001.
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fied, TGR5 expression was conserved only in Mc-M/s. In
contrast, its expression was down-regulated in other fully
differentiated mononuclear cell lineages. Interestingly, an
effect of IFN-c was only observed when IFN-c was added
at the initial phase of differentiation. These results suggest
that IFN-c may contribute to conserved expression of
TGR5 in monocytes.
Recently, it has been suggested that TGR5 plays a role
in immunological regulation via cAMP, a second
messenger with an immunoregulatory function.16,17,27,28
Based on the inhibiting effect of inhibitor of nuclear fac-
tor-jBa (IjBa), Wang et al.32 reported an inhibitory
mechanism of NF-jB, in which TGR5 enhances the cyto-
solic protein b-arrestin 2 that inhibits phosphorylation of
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Figure 4. cAMP related to TGR5 as a second messenger suppresses tumour necrosis factor-a (TNF-a) production from macrophages differenti-
ated with macrophage colony-stimulating factor (M-CSF) and interferon-c (IFNc) (Mc-M/s) stimulated by Enterococcus faecalis or lipopolysac-
charide (LPS). (a) Differentiated Mc-M/s stimulated by E. faecalis (100 multiplicity of infection) on day 6 were treated with cAMP (10, 25 and
50 lM). TNF-a levels in culture supernatants were analysed after 24 hr of stimulation. Results are shown as the means  SEM from four inde-
pendent experiments as relative percentages of the TNF-a levels in Mc-M/s stimulated with E. faecalis only. Statistical analysis was performed by
Kruskal–Wallis one-way analysis of variance (ANOVA) and the Bonferroni post-hoc test for multiple comparisons. **P < 001. (b) Similar TNF-a
analysis as in (a) stimulated with LPS (100 ng/ml) with or without cAMP. Results are shown as the means  SEM from six independent experi-
ments as relative percentages of the TNF-a levels in Mc-M/s stimulated with LPS only. Statistical analysis was performed by Kruskal–Wallis one-
way ANOVA and the Bonferroni post-hoc test for multiple comparisons. **P < 001. (c) Cell viability of Mc-M/s modified by cAMP. Mc-M/s
were differentiated from monocytes by 6 days of culture with M-CSF and IFNc (control). cAMP (10, 25 and 50 lM) was added on day 6. Cell
viability was measured by PrestoBlue Cell Viability Reagent. Results are shown as the means  SEM from each three independent experiments as
relative percentages of the viability of Mc-M/s stimulated with E. faecalis only. Statistical analysis was performed by Kruskal–Wallis one-way ANO-
VA. (d) cAMP production in Mc-M/s stimulated by the TGR5 agonist. Results are shown as the means  SEM from five independent experi-
ments. Statistical analysis was performed by the Student’s t-test. *P < 005. (e) On day 6, Mc-M/s were treated with the TGR5 agonist (10 lM)
or control medium for 120 min and then stimulated by LPS (10 ng/ml) or control medium. Western blotting of c-Fos, p-c-Fos and b-actin at 0,
5, 15, 30 and 60 min is shown.
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IjBa by bacterial antigen stimulation, resulting in sup-
pression of TNF-a production. Pols et al.27 also reported
that TGR5 induces a decrease of phospho-IjBa (p-IjBa).
Based on these results, we also examined whether TGR5
inhibits phosphorylation of IjBa, but the TGR5 agonist
did not affect the level of p-IjBa in Mc-M/s (data not
shown). In other studies, Koga et al.33 demonstrated that
cAMP induced by prostaglandin E2 suppresses TNF-a
transcription by up-regulation of c-Fos that binds to
nuclear factor-jB p65 protein, and this complex cannot
bind to the TNF promoter in DCs or RAW264.7 cells. In
addition, c-Fos is stabilized by phosphorylation from Ij
kinase b via the toll-like receptor 4 pathway that is trig-
gered by innate immune responses against bacterial anti-
gen.33 This inhibition of the TNF-a promoter binding
effect is not associated with IjBa. We hypothesized that
in mononuclear cell lineages, TGR5 has an immunoregu-
latory function by inducing cAMP, which is similar to
the mechanism of prostaglandin E2. In our experiments,
the concentration of cAMP in Mc-M/s was increased by
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Figure 5. Lamina propria mononuclear cells (LPMCs) from patients with Crohn’s disease CD express TGR5 similarly to that in macrophages
differentiated with macrophage colony-stimulating factor (M-CSF) and interferon-c (IFNc) (Mc-M/s). (a) The mRNA level of TGR5 in LPMCs
of non-irritable bowel disease (non-IBD), non-inflamed Crohn’s disease (CD) and inflamed CD patients was measured by real-time quantitative
PCR. The mRNA level of TGR5 was normalized to that of b-actin and is shown as the fold change based on the non-IBD, which is set to 1.
Results are shown as the means  SEM from four non-IBD, seven non-inflamed CD and seven inflamed CD samples. Statistical analysis was per-
formed by Kruskal–Wallis one-way analysis of variance and the Bonferroni post-hoc test for multiple comparisons. *P < 005. (b) The mRNA
level of TGR5 in CD14+-depleted LPMCs and CD14+ intestinal M/s from CD patients was measured by real-time quantitative PCR. The mRNA
level of TGR5 was normalized to that of b-actin, and is shown as the fold change based on the mRNA levels in CD whole LPMCs before sorting.
Results are shown as the means  SEM from four CD14+-depleted LPMCs and four CD14+ intestinal M/s samples. Statistical analysis was
performed by Kruskal–Wallis one-way analysis of variance and the Bonferroni post-hoc test for multiple comparisons. *P < 005.
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Figure 6. The TGR5 agonist suppresses tumour necrosis factor-a (TNF-a) production from the lamina propria mononuclear cells (LPMCs) and
CD14+ intestinal macrophages (M/s) of patients with Crohn’s disease (CD) in the same manner as that of macrophages differentiated with
macrophage colony-stimulating factor (M-CSF) and interferon-c (IFNc) (Mc-M/s) stimulated by Enterococcus faecalis. (a) TNF-a levels in CD
LPMC culture supernatants were analysed after 24 hr stimulation with E. faecalis (multiplicity of infection = 100) with or without the TGR5 ago-
nist (1, 33 and 10 lM). Results are shown as the means  SEM from five independent experiments as relative percentages of TNF-a levels in
LPMCs stimulated with E. faecalis only. Statistical analysis was performed by Kruskal–Wallis one-way analysis of variance and the Bonferroni
post-hoc test for multiple comparisons. *P < 005, **P < 001. (b) CD14+ intestinal M/s of CD patients were analysed as described in (a).
Results are shown as the means  SEM from three independent experiments as relative percentages of TNF-a levels in CD14+ intestinal M/s
stimulated with E. faecalis only. Statistical analysis was performed by Kruskal–Wallis one way analysis of variance and the Bonferroni post-hoc test
for multiple comparisons. **P < 001.
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treatment with the TGR5 agonist that induced phosphor-
ylation of c-Fos (p-c-Fos). These findings suggest that the
TGR5 agonist may suppress TNF-a transcription via p-c-
Fos in Mc-M/s.
Several BAs, including both primary and secondary
BAs, have been reported as natural ligands of TGR5. Of
these BAs, LCA activates TGR5 with an EC50 of
~ 600 nM, suggesting that LCA is a physiological ligand
for TGR5, whereas UDCA has low affinity.17,24,34 Consis-
tent with previous observations, our study indicated that
DCA and LCA had an anti-inflammatory potential
(Fig. 3c). In our study, the TGR5 agonist and BAs did
not affect the viability of M/s (Fig. 3d,e). Although the
detailed mechanism is not clarified on the Mc-M/s, Sato
et al.35 investigated the binding affinity of BAs to TGR5
from the aspect of chemical structures by luciferase assay
methods on TGR5-transfected Chinese hamster ovary
(CHO) cells. They revealed that TGR5 were highly bound
to LCA, DCA, CDCA, CA and UDCA in this order. Their
binding affinity to TGR5 was affected by the absence or
existence of hydroxylation in positions 6, 7 and 12 of the
steroid ring, which was constituted of bile acids. LCA and
DCA do not have a hydroxylation at 7 of the steroid ring,
but others have one. It is possible that the binding affin-
ity to TGR5 on the Mc-M/s depends on the molecular
structure of BAs. Both DCA and LCA have fewer hydro-
xyl groups, suggesting that a hydrophobic structure facili-
tates binding to TGR5.
Importantly, the TGR5 agonist suppressed TNF-a pro-
duction by intestinal CD14+ M/s that play a central role
in the pathogenesis of CD. Modification and condition-
ing of innate immune cells have been considered as ther-
apeutic strategies for treating chronic inflammatory
disorders such as CD. Previously, we reported that te-
tomilast (OPC-6535), which inhibits phosphodiesterase-
4, suppresses production of pro-inflammatory cytokines
in human M/s.36 Retinoic acid receptors and TGR5
affect the differentiation process of DCs and induce an
IL-12-hypoproducing DC phenotype.15,16 Here, we dem-
onstrated that a TGR5 agonist suppressed TNF-a
production by the inflammatory phenotype of M/s.
Although a precise mechanism remains unclear, Cipriani
et al.28 reported that TGR5 is associated with regulation
of experimental colitis in a mouse model by not only
inflammatory cytokine suppression in immune cells, but
also by maintaining the epithelial architecture as shown
by an abnormal distribution of the epithelial tight junc-
tion protein zonulin 1 on the colon in dextran sulphate
sodium-induced colitis in TGR5-deficient mice. These
results suggest that TGR5 is involved in intestinal
homeostasis by regulation of the immune cell response
and maintenance of the epithelial barrier function.
In conclusion, our results clearly demonstrate the
expression profiles of TGR5 in several mononuclear cell
types and the potential of a TGR5 agonist as an anti-
inflammatory molecule in innate immune cells. Modifica-
tion of TGR5 signalling may have a potential to regulate
immune reaction in chronic inflammatory disorders such
as CD.
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Figure S1. Morphology and expression of cell surface
markers in macrophages differentiated with macrophage
colony-stimulating factor and interferon-c (Mc-M/s) and
macrophages differentiated with macrophage colony-stim-
ulating factor only (M-M/s).
Figure S2. The tumour necrosis factor-a assay is not
influenced by solvents.
Figure S3. The TGR5 agonist cannot inhibit tumour
necrosis factor-a production from macrophages differen-
tiated with macrophage colony-stimulating factor alone
(M-M/s), dendritic cells (DCs) and macrophages differ-
entiated with granulocyte–macrophage colony-stimulating
factor (GM-M/s.
Figure S4. The TGR5 agonist cannot inhibit interleu-
kin-10 production from macrophages differentiated with
macrophage colony-stimulating factor and interferon-c
(Mc-M/s).
Figure S5. Surface phenotypes on the macrophages dif-
ferentiated with macrophage colony-stimulating factor
and interferon-c (Mc-M/s) modified with or without the
TGR5 agonist.
Figure S6. Tumour necrosis factor-a levels in periph-
eral CD14+ monocytes culture supernatants were analysed
after 24 hr stimulation with lipopolysaccharide (LPS;
100 ng/ml) with or without the TGR5 agonist (1, 33 and
10 lM).
Figure S7. Inflamed Crohn’s disease lamina propria
mononuclear cells (CD LPMCs) had higher tumour
necrosis factor-a level than non-inflamed.
Figure S8. Effects of the TGR5 agonist on tumour
necrosis factor-a production from several subsets of Cro-
hn’s disease lamina propria mononuclear cells (CD
LPMCs) stimulated with Enterococcus faecalis.
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